This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study will evaluate the performance and safety of OROSEDAL in children and adults with sore throat or minor oral lesions, including minor aphthous ulcers and histologically confirmed oral lichen planus. OROSEDAL is prescribed in routine practice before inclusion. Patients will be followed for 6 ± 1 days and will complete self-assessments of pain, swallowing discomfort, treatment use, and adverse events.

OROSEDAL is a CE-marked medical device intended to relieve sore throat, aphthous ulcers, oral lichen planus, and minor mouth lesions through a mechanical barrier and hydrating effect. The study is conducted in French general practice under real-life conditions of use. The decision to prescribe OROSEDAL is made independently from study participation. Eligible patients aged 8 years or older with sore throat or minor oral lesions evolving for less than 15 days and baseline global pain intensity >40 mm on a 0-100 mm visual analog scale will be enrolled. Data will be collected at inclusion, through a daily self-assessment diary, and at Day 6 ± 1 day or early termination. The primary endpoint is the proportion of patients with a reduction >20 mm in global pain intensity over the previous 24 hours between Day 0 and Day 1 evening. Secondary endpoints assess pain response at Day 6, immediate pain relief after first use, daily pain evolution, swallowing discomfort, global patient-rated effectiveness, associated symptoms, safety/tolerability, device deficiencies, and compliance.

Inclusion Criteria:

• Age 8 years or older, including adults.
• Sore throat or minor mouth lesion, including minor aphthous ulcer or histologically confirmed oral lichen planus, evolving for less than 15 days.
• Global pain intensity over the previous 24 hours, spontaneous and/or during chewing or swallowing, >40 mm on a 0-100 mm visual analog scale.
• OROSEDAL prescription decided by the investigator before inclusion.
• Written informed consent from the patient or from one parent for minors.

Exclusion Criteria:

• More than 3 visible oral mucosal lesions.
• Post-intubation sore throat.
• Corticosteroid use ongoing or within 3 days before inclusion.
• NSAID use ongoing or within 3 days before inclusion.
• Local treatment on the lesion ongoing or within 3 days before inclusion.
• Non-opioid analgesics, including paracetamol, ongoing or within 3 days before inclusion, unless continued for at least 24 hours at the same daily dose as during the 24 hours before inclusion.
• Weak or strong opioid analgesics ongoing or within 3 days before inclusion.
• Signs suggesting a condition requiring additional investigations according to the investigator, except rapid streptococcal throat testing.
• Signs suggesting a condition requiring corticosteroid prescription according to the investigator.
• Systemic disease, such as rheumatoid arthritis, lupus, or Behçet disease.
• Any contraindication listed in OROSEDAL instructions for use.
• Known allergy to any OROSEDAL component, including glycerol, tamarind extract, mallow extract, benzyl alcohol, orange blossom flavoring, or xylitol.
• Non-compliance with precautions for use listed in the instructions for use.

Children and adults aged 8 years or older consulting French general practitioners for sore throat or minor oral lesions, including minor aphthous ulcers or histologically confirmed oral lichen planus, for whom OROSEDAL has been prescribed in routine care.